Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

Pleural effusion (PE) represents the leading cause of dasatinib (DAS) discontinuation. However, the pathogenic mechanism of this adverse event (AE) is unknown and its management unclear. We investigated if a DAS dose reduction after the first PE would prevent the recurrence of this AE. We retrospect...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of hematology 2018, Vol.97 (1), p.95-100
Hauptverfasser:	Iurlo, Alessandra, Galimberti, Sara, Abruzzese, Elisabetta, Annunziata, Mario, Bonifacio, Massimiliano, Latagliata, Roberto, Pregno, Patrizia, Ferrero, Dario, Sorà, Federica, Orlandi, Ester Maria, Fava, Carmen, Cattaneo, Daniele, Bucelli, Cristina, Binotto, Gianni, Pungolino, Ester, Tiribelli, Mario, Gozzini, Antonella, Gugliotta, Gabriele, Castagnetti, Fausto, Stagno, Fabio, Rege-Cambrin, Giovanna, Martino, Bruno, Luciano, Luigiana, Breccia, Massimo, Sica, Simona, Bocchia, Monica, Pane, Fabrizio, Saglio, Giuseppe, Rosti, Gianantonio, Specchia, Giorgina, Cortelezzi, Agostino, Baccarani, Michele
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Dasatinib - therapeutic use Female Gene Expression Regulation, Leukemic - drug effects Hematology Humans Italy - epidemiology Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - epidemiology Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Male Medicine Medicine & Public Health Middle Aged Oncology Original Article Pleural Effusion - drug therapy Pleural Effusion - epidemiology Pleural Effusion - genetics Recurrence Retrospective Studies Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!